Product Description
a vaccine, to patients with solid tumors that express NY-ESO-1 antigen; IMF-001 is a CHP-NY-ESO-1 complex consisting of recombinant NY-ESO-1 protein and cholesteryl hydrophobized pullulan (CHP). CHP forms colloidally stable nanoparticles in water and complexes with substrate such as NY-ESO-1 protein. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01234012)
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ImmunoFrontier
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Esophageal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
JapicCTI-101088 | P1 |
Active |
Esophageal Cancer |
2011-06-30 |